Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

FERRIPROX 100MG/ML ORAL SOLUTION [SIN13668P]

Active ingredients: DEFERIPRONE

View product's general information
Last updated on 9 October 2026

Product Info

FERRIPROX 100MG/ML ORAL SOLUTION

[SIN13668P]

Product information

Active Ingredient and Strength

DEFERIPRONE - 100 G/L

Dosage Form

SOLUTION

Manufacturer and Country

APOTEX INC.- RICHMOND HILL SITE - CANADA

Registration Number

SIN13668P

Licence Holder

PHARMAFORTE SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

V03AC02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.

Dosing

4.2 Posology and method of administration

For oral use.

Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia.

Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. Dose per kilogram body weight should be calculated to the nearest 2.5 ml. See table below for recommended doses for body weights at 10 kg increments.

Doses above 100 mg/kg/day are not recommended because of the potentially increased risk of adverse reactions (see sections 4.4, 4.8, and 4.9 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

There are limited data available on the use of deferiprone in children between 6 and 10 years of age, and no data on deferiprone use in children under 6 years of age.

Due to the serious nature of agranulocytosis, that can occur with the use of deferiprone, special monitoring is required for all patients. Caution must be used when the patients’ absolute neutrophil count (ANC) is low, as well as when treating patients with renal insufficiency or hepatic dysfunction. (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Dose table

To obtain a dose of about 75 mg/kg/day, use the volume of oral solution suggested in the following table for the body weight of the patient. Sample body weights at 10 kg increments are listed.

Ferriprox Oral Solution Dosage Table 1



Contraindications

4.3 Contraindications

  • Hypersensitivity to the active substance or to any of the excipients.

  • History of recurrent episodes of neutropenia.

  • History of agranulocytosis.

  • Pregnancy or breast-feeding (see section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

  • Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).